Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer.
nab-paclitaxel
ficlatuzumab
gemcitabine
metastatic pancreatic cancer
phase Ib clinical trial
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
08 05 2023
08 05 2023
Historique:
received:
26
10
2022
accepted:
20
12
2022
medline:
10
5
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
In preclinical pancreatic ductal adenocarcinoma (PDAC) models, inhibition of hepatocyte growth factor (HGF) signaling using ficlatuzumab, a recombinant humanized anti-HGF antibody, and gemcitabine reduced tumor burden. Patients with previously untreated metastatic PDAC enrolled in a phase Ib dose escalation study with 3 + 3 design of 2 dose cohorts of ficlatuzumab 10 and 20 mg/kg administered intravenously every other week with gemcitabine 1000 mg/m2 and albumin-bound paclitaxel 125 mg/m2 given 3 weeks on and 1 week off. This was followed by an expansion phase at the maximally tolerated dose of the combination. Twenty-six patients (sex, 12 male:14 female; median age, 68 years [range, 49-83 years]) were enrolled, 22 patients were evaluable. No dose-limiting toxicities were identified (N = 7 pts) and ficlatuzumab at 20 mg/kg was chosen as the maximum tolerated dose. Among the 21 patients treated at the MTD, best response by RECISTv1.1: 6 (29%) partial response, 12 (57%) stable disease, 1 (5%) progressive disease, and 2 (9%) not evaluable. Median progression-free survival and overall survival times were 11.0 months (95% CI, 7.6-11.4 months) and 16.2 months (95% CI, 9.1 months to not reached), respectively. Toxicities attributed to ficlatuzumab included hypoalbuminemia (grade 3, 16%; any grade, 52%) and edema (grade 3, 8%; any grade, 48%). Immunohistochemistry for c-Met pathway activation demonstrated higher tumor cell p-Met levels in patients who experienced response to therapy. In this phase Ib trial, ficlatuzumab, gemcitabine, and albumin-bound paclitaxel were associated with durable treatment responses and increased rates of hypoalbuminemia and edema.
Sections du résumé
BACKGROUND
In preclinical pancreatic ductal adenocarcinoma (PDAC) models, inhibition of hepatocyte growth factor (HGF) signaling using ficlatuzumab, a recombinant humanized anti-HGF antibody, and gemcitabine reduced tumor burden.
METHODS
Patients with previously untreated metastatic PDAC enrolled in a phase Ib dose escalation study with 3 + 3 design of 2 dose cohorts of ficlatuzumab 10 and 20 mg/kg administered intravenously every other week with gemcitabine 1000 mg/m2 and albumin-bound paclitaxel 125 mg/m2 given 3 weeks on and 1 week off. This was followed by an expansion phase at the maximally tolerated dose of the combination.
RESULTS
Twenty-six patients (sex, 12 male:14 female; median age, 68 years [range, 49-83 years]) were enrolled, 22 patients were evaluable. No dose-limiting toxicities were identified (N = 7 pts) and ficlatuzumab at 20 mg/kg was chosen as the maximum tolerated dose. Among the 21 patients treated at the MTD, best response by RECISTv1.1: 6 (29%) partial response, 12 (57%) stable disease, 1 (5%) progressive disease, and 2 (9%) not evaluable. Median progression-free survival and overall survival times were 11.0 months (95% CI, 7.6-11.4 months) and 16.2 months (95% CI, 9.1 months to not reached), respectively. Toxicities attributed to ficlatuzumab included hypoalbuminemia (grade 3, 16%; any grade, 52%) and edema (grade 3, 8%; any grade, 48%). Immunohistochemistry for c-Met pathway activation demonstrated higher tumor cell p-Met levels in patients who experienced response to therapy.
CONCLUSION
In this phase Ib trial, ficlatuzumab, gemcitabine, and albumin-bound paclitaxel were associated with durable treatment responses and increased rates of hypoalbuminemia and edema.
Identifiants
pubmed: 36807743
pii: 7046246
doi: 10.1093/oncolo/oyad002
pmc: PMC10166179
doi:
Substances chimiques
Gemcitabine
0
130-nm albumin-bound paclitaxel
0
ficlatuzumab
77E89833TG
Albumin-Bound Paclitaxel
0
Paclitaxel
P88XT4IS4D
Albumins
0
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
425-432Informations de copyright
© The Author(s) 2023. Published by Oxford University Press.
Références
Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S7-S19
pubmed: 22128289
J Clin Oncol. 2007 May 20;25(15):1960-6
pubmed: 17452677
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Clin Pharmacol Drug Dev. 2018 Jun;7(5):532-542
pubmed: 29346833
Br J Cancer. 2020 May;122(10):1486-1495
pubmed: 32203220
Clin Cancer Res. 2013 Sep 15;19(18):5068-78
pubmed: 23894056
Eur J Cancer. 2011 Jul;47(10):1476-83
pubmed: 21600759
Blood Cancer Discov. 2021 Sep;2(5):434-449
pubmed: 34514432
J Clin Pharmacol. 2013 Nov;53(11):1103-11
pubmed: 23922054
Am J Clin Oncol. 2003 Jun;26(3):247-51
pubmed: 12796593
Br J Cancer. 2016 Feb 2;114(3):269-80
pubmed: 26766740
Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6152-8
pubmed: 15448002
Neoplasma. 2004;51(3):209-13
pubmed: 15254675
Gastroenterology. 2011 Dec;141(6):2218-2227.e5
pubmed: 21864475
PLoS One. 2015 Oct 07;10(10):e0139679
pubmed: 26445503
Genes Dev. 2016 Jan 15;30(2):233-47
pubmed: 26773005
Mol Cancer Ther. 2014 Feb;13(2):540-52
pubmed: 24258345
Cancers (Basel). 2020 Jun 11;12(6):
pubmed: 32545260
Cancer Res. 2007 Nov 1;67(21):10309-16
pubmed: 17974973
Br J Cancer. 2014 Jul 15;111(2):272-80
pubmed: 24901237
Clin Cancer Res. 2010 Jan 15;16(2):699-710
pubmed: 20068101
BMC Cancer. 2015 Feb 19;15:71
pubmed: 25884642
Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96
pubmed: 23882082
Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25
pubmed: 14685170
Oncology. 2002;63(3):286-96
pubmed: 12381909
Wound Repair Regen. 2006 Jan-Feb;14(1):2-10
pubmed: 16476066
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Clin Cancer Res. 2014 May 15;20(10):2793-804
pubmed: 24634378
Pancreas. 2011 May;40(4):608-14
pubmed: 21499215